- /
- Supported exchanges
- / US
- / LLY.NYSE
Eli Lilly and Company (LLY NYSE) stock market data APIs
Eli Lilly and Company Financial Data Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd; Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease, as well as Strategic partnership with NVIDIA Corporation for development of supercomputer. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Eli Lilly and Company (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Eli Lilly and Company data using free add-ons & libraries
Get Eli Lilly and Company Fundamental Data
Eli Lilly and Company Fundamental data includes:
- Net Revenue: 59 420 M
- EBITDA: 28 729 M
- Earnings Per Share: 20
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 6.37
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eli Lilly and Company News
New
Trump inks Eli Lilly & Novo deals: How to play pharma stocks
US President Trump announced deals with Novo Nordisk (NVO) and Eli Lilly (LLY) to secure lower prices of the companies' GLP-1 drugs. Bernstein US biopharmaceuticals senior analyst Courtney Breen join...
Trump drug pricing deal may squeeze Novo, Lilly margins, expert says
STORY: "I think initially, [stocks] rallied on the idea that, 'Hey, we're going to have the opportunity to sell more of this product to more and more people, that should be good for us," Landsberg sai...
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles des...
Stock market today: Dow, S&P 500, Nasdaq fall as Nvidia leads AI trade lower, jobs jitters reignite
US stocks resumed a steep slide Thursday as concerns about Big Tech continued to dog markets and private jobs data showed a tough month for layoffs in October, spurring a rally in bonds. The tech-hea...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.